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345* Survival factors in cystic ﬁbrosis: a case-control study
N.J. Simmonds1,2, S.J. MacNeill2, P. Cullinan1,2, M.E. Hodson1,2. 1Royal
Brompton Hospital, London, United Kingdom; 2Imperial College, London, United
Kingdom
Rationale: There are a myriad of factors (including environmental, healthcare-
related and socioeconomic) which may be important in long-term survival in CF.
It has been noted there is a poor genotype-phenotype relationship. The aim of this
study was to identify these factors.
Methods: The CF database at the Royal Brompton Hospital was used to identify
long-term survivors (patients who had reached 40 yrs of age (without transplan-
tation) ‘cases’). Cases were age-matched with at least one control who died or
was transplanted before reaching age 30. Late diagnosis patients were excluded.
Conditional logistic regression models were used to identify potential inﬂuences on
survival.
Results: 78 cases and 152 controls were analysed, producing 1811 matched pairs.
97% were pancreatic insufﬁcient. Of 26 factors investigated, high BMI (OR 1.52,
95% CI 1.35−1.72), FEV1 (OR 1.62, 1.44−1.82) and FVC (OR 1.71, 1.48−1.96) at
transfer to the clinic, resulted in increased probabilities of survival after adjusting
for age and sex. Factors associated with a reduced probability of survival included:
CF diagnosis <5 yrs (OR 0.46, 0.28−0.76); referral from a paediatric clinic in a
deprived area (OR 0.12, 0.04−0.34); and S. aureus or P. aeruginosa colonisation
before 16 yrs (OR 0.36, 0.14−0.89 & 0.18, 0.06−0.58, respectively). Factors not
inﬂuencing survival included: sex, development of diabetes before 16 yrs, parents’
occupation, number of siblings and school achievements.
Conclusion: In a very carefully matched study we failed to identify major environ-
mental determinants of long-term survival in early diagnosis CF. Findings suggest
that the majority of signiﬁcant factors were directly related to optimal physical
parameters and avoiding bacterial colonisation.
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Objective: To compare the clinical characteristics of patients with cystic ﬁbrosis
(CF) diagnosed in childhood and reached adulthood and of patients diagnosed in
adulthood.
Patients and Methods: Data were reviewed retrospectively of 335 patients
diagnosed with CF at Hacettepe University Pediatric Pulmonary Diseases Unit
between 1981 and December 2006.
Results: Of 335 CF patients, 26 (7.8%) were diagnosed in childhood and reached
adulthood (Group 1) and 11 (3.2%) were diagnosed in adulthood (16 years old)
(Group 2). All the patients in Group 2 were diagnosed after 1993. Ten of 11 patients
(91%) in Group 2 and 19 of 26 patients (73%) in Group 1 were diagnosed with
pulmonary symptoms. In Group 1, three patients are DF508 homozygous, while
none of them have this homozygote genotype in Group 2. No patient had liver
disease in Group 2, but seven patients (27%) in Group 1 had. Other clinical problems
respectively in Group 1 and Group 2 were diabetes mellitus in two patients (7.6%)
and in two patients (22%), osteoporosis in nine patients (35%) and in two patients
(22%), bronchial hyperreactivity in 10 patients (38%) and in two patients (22%).
Conclusion: Patients with CF diagnosed in adulthood in our center often present
with pulmonary symptoms and they usually have mild other CF related diseases.
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The Belgian CF registry (BMR-RBM)was initiated in 1998. A dataset of 200 ﬁelds
was created containing demographic, diagnostic, clinical and social variables. The
data collection was initially performed on a paper questionnaire with data input
in a MS Access database. Annual reports were generated using ad hoc query’s
and Excel statistical calculations. After 5 years the project was reviewed on a
quality/efﬁciency basis. It implied database cleansing (remove inconsistent data,
clean double or incomplete data, consolidate data). Input screens were updated and
a trilingual interface developed. Automated identity recognition (multi-parametric
code), data integrity control, validation limits and logical error controls were
introduced. Tables were reconstructed. Algorithms are run repeatedly until all errors
are cleared manually and the data can be transferred to the core. Recurrent jobs
were automated (SQL). A decentralized input programme on cd-rom was made
available to the CF centres since 2005. The results show a clean patient database
for over 1100 individuals with CF and how a descriptive system evolves into a
knowledge base ready for scientiﬁc research. The core of the database is a dual
(one to many) structure containing a table with all registered variables and a
demographics/genetics table with the most recently collected data. Data harvesting
and annual report generation are much less time consuming. Individual CF-centres
reports were included. The user interface is easily transferable to any language.
Migration to a web-based system can be considered. Since the end of 2006 the
registry is based at the Scientiﬁc Institute of Public Health.
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The Belgian CF Registry was founded in 1998 by clinicians caring for a large
number of persons with CF. The aims were to follow the natural evolution of the
disease (no previous data available), provide a tool for epidemiological research
and inform the community. The method chosen was the study of survivors already
diagnosed and widely used by other countries. Demographics, diagnostic and
genetic data were annually completed with vital clinical parameters, complications,
therapies and social information. After informed consent the practitioners registered
data on a pre-printed form with 200 items until 2004, now on a cd-rom. Processing
is centralized in a MS Access database. Results of analytical statistics are compiled
in an annual report. The full data base includes over 1100 patients vs. 534 in 1998
and covers about 90% of the estimated CF population. The maximum age reached
was 59 years, 46% of the patients are older than 18, 60% were diagnosed before
the age of 1 year. 70% of the alleles carry the DF508 mutation. The incidence
of Pseudomonas aeruginosa decreased since 1998, the degree of resistance to
antibiotics increased, Burholderia cepacia remained low (0.7%). Recently over 45%
of the 6 to 18 years showed normal pulmonary function, 28% mild disease. Figures
about complications and therapy match international data. The major beneﬁt of the
registry is informative to the clinicians. Comparison with similar studies is good
and sustains the quality of care provided in Belgium. Additional information to
researchers or governmental agencies is being worked out. Longitudinal studies,
speciﬁc additions (transplant follow-up, socio-economical study) and international
cooperation are ongoing projects.
